CERE earnings
Cerevel Therapeutics Holdings Inc. (CERE) earnings releases and earnings dates - real-time wire coverage of every quarterly report.
Recent earnings items
- AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience PipelineProposed acquisition adds robust pipeline of assets focused on best-in-class potential for psychiatric and neurological disorders where significant unmet needs remainCerevel's clinical-stage pipeline complements AbbVie's current on-market portfolio and emerging neuroscience pipelineEmraclidine has the potential to transform the standard of care in schizophrenia and other psychiatric conditionsTransaction valued at $45.00 per share in cash, for a total equity value of approximately $8.7 billionAbbVie to hold an investor conference call tomorrow, December 7, at 8:00 a.m. CTNORTH CHICAGO, Ill. and CAMBRIDGE, Mass., Dec. 6, 2023 /PRNewswire/ -- AbbVie Inc. (NYSE:ABBV) and Cerevel Therapeutics (N
- Cerevel Therapeutics to Report Third Quarter 2023 Financial Results and Business Updates on Wednesday, November 1, 2023CAMBRIDGE, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report third quarter 2023 financial results and business updates on Wednesday, November 1, 2023, before the U.S. financial markets open. Management will host a conference call to discuss third quarter financial results and business updates on Wednesday, November 1 at 8:00 a.m. ET. To access the call, please register at this link. Once registered, you will receive the dial-in information and a unique PIN number. A live webcast of the call, along with supporting slides, will be availabl
- Cerevel Therapeutics Reports Second Quarter 2023 Financial Results and Business UpdatesThree new executives added to leadership team: Ron Renaud, Susan Altschuller, Paul Burgess Emraclidine EMPOWER data now expected second half 2024 Darigabat ADAPT trial in panic disorder initiated Cash, cash equivalents, and marketable securities of $825.1 million as of June 30, 2023, expected to support a data-rich 2024 and fund operations into 2025 Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today reported financial results for the second quarter ended June 30, 2023 and provided key pipeline and business updat
- Cerevel Therapeutics to Report Second Quarter 2023 Financial Results and Business Updates on Wednesday, August 2, 2023CAMBRIDGE, Mass., July 05, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report second quarter 2023 financial results and business updates on Wednesday, August 2, 2023, before the U.S. financial markets open. Management will host a conference call to discuss second quarter financial results and business updates on Wednesday, August 2 at 8:00 a.m. ET. To access the call, please register at this link. Once registered, you will receive the dial-in information and a unique PIN number. A live webcast of the call, along with supporting slides, will be available on
- Cerevel Therapeutics Appoints Ron Renaud as President and Chief Executive Officer and Reports First Quarter 2023 Financial ResultsRon Renaud to succeed Tony Coles, M.D. as CEO, effective June 12, 2023; Dr. Coles will continue as chairperson of the board Mr. Renaud brings more than 25 years of biotechnology leadership to Cerevel, including two prior CEO roles and strong financial and operational experience Emraclidine Phase 2 schizophrenia data readout on track for 1H 2024 Darigabat Phase 2 epilepsy data readout expected mid-year 2024; panic disorder Phase 2 trial expected to initiate in Q2 2023 Cash, cash equivalents, and marketable securities of $863.0 million as of March 31, 2023, expected to support seven data readouts in 2024 and fund operations into 2025 Conference call today at 8:00 a.m. ET CAMBRIDGE, Mas
- Cerevel Therapeutics to Report First Quarter 2023 Financial Results and Business Updates on Wednesday, May 3, 2023CAMBRIDGE, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report first quarter 2023 financial results and business updates on Wednesday, May 3, 2023, before the U.S. financial markets open. Management will host a conference call to discuss first quarter financial results and business updates on Wednesday, May 3 at 8:00 a.m. ET. To access the call, please register at this link. Once registered, you will receive the dial-in information and a unique PIN number. A live webcast of the call, along with supporting slides, will be available on the in
- Cerevel Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates on Wednesday, February 22, 2023CAMBRIDGE, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report fourth quarter and full year 2022 financial results and business updates on Wednesday, February 22, 2023, before the U.S. financial markets open. Management will host a conference call to discuss fourth quarter and full year 2022 financial results and business updates on Wednesday, February 22 at 8:00 a.m. ET. To access the call, please register at this link. Once registered, you will receive the dial-in information and a unique PIN number. A live webcast of the call, along with
- Cerevel Therapeutics to Report Third Quarter 2022 Financial Results and Pipeline Update on Tuesday, November 8, 2022CAMBRIDGE, Mass., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report third quarter 2022 financial results on Tuesday, November 8, 2022, before the U.S. financial markets open. Management will host a conference call to discuss third quarter 2022 financial results and recent business updates on Tuesday, November 8, 2022, at 8:00 a.m. ET. To access the call, please register at this link. Once registered, you will receive the dial-in information and a unique PIN number.A live webcast of the call, along with supporting slides, will be available on the i
- Cerevel Therapeutics Reports Second Quarter 2022 Financial Results and Business UpdatesInitiated two parallel, adequately-powered Phase 2 trials of emraclidine in schizophrenia with data expected 1H 2024 Phase 1 trial of emraclidine to be initiated by year-end to support future development in Alzheimer's disease psychosis Panic disorder selected as second indication for darigabat, planning underway for Phase 2 proof-of-concept Cash, cash equivalents and marketable securities of $531M as of June 30, 2022, expected to support operations into 2024 Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today r
- Cerevel Therapeutics to Report Second Quarter 2022 Financial Results and Pipeline Update on Monday, August 1, 2022CAMBRIDGE, Mass., July 25, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report second quarter 2022 financial results on Monday, August 1, 2022, before the U.S. financial markets open. Management will host a conference call to discuss second quarter 2022 financial results and recent business updates on Monday, August 1, 2022 at 8:00 a.m. ET. To access the call, please register at this link. Once registered, you will receive the dial-in information and a unique PIN number.A live webcast of the call, along with supporting slides, will be available on the invest
- Cerevel Therapeutics Reports First Quarter 2022 Financial Results and Business UpdatesOn track to initiate two parallel adequately-powered Phase 2 trials of emraclidine in schizophrenia by mid-year 2022 Data for the darigabat Phase 2 proof-of-concept trial in focal epilepsy now expected mid-year 2023, revised from 2H 2022 $550.9M in cash, cash equivalents and marketable securities as of March 31, 2022; additional $37.5M from tavapadon risk-sharing arrangement received in April 2022 Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today reported financial results for the quarter ended March 31, 2022 and
- Cerevel Therapeutics to Report First Quarter 2022 Financial Results and Pipeline Update on Tuesday, May 10, 2022CAMBRIDGE, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report first quarter 2022 financial results on Tuesday, May 10, 2022, before the U.S. financial markets open. Management will host a conference call to discuss first quarter 2022 financial results and recent business updates on Tuesday, May 10, 2022 at 8:00 a.m. ET. To access the call, please dial (833)-665-0655 (domestic) or (702)-495-1044 (international) and refer to conference ID 4497847.A live webcast of the call, along with supporting slides, will be available on the investors
- Cerevel Therapeutics Provides Update on Pipeline Progress along with Fourth Quarter and Full Year 2021 Financial ResultsAnnounced positive results from Phase 1 healthy volunteer trial of darigabat in acute anxiety On track to initiate two parallel adequately-powered Phase 2 trials of emraclidine in schizophrenia by mid-year 2022 Multiple late-stage clinical readouts expected in the next 18 months Conference call today at 8:00 AM EST CAMBRIDGE, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided key business updates. "Cerevel continues to demonstrate that our targeted approach to
- Cerevel Therapeutics to Report Fourth Quarter 2021 Financial Results and Pipeline Update on Tuesday, March 1, 2022CAMBRIDGE, Mass., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report fourth quarter 2021 financial results on Tuesday, March 1, 2022, before the U.S. financial markets open. Management will host a conference call to discuss fourth quarter 2021 financial results and recent business updates on Tuesday, March 1, 2022 at 8:00 a.m. ET. To access the call, please dial 833-665-0655 (domestic) or 702-495-1044 (international) and refer to conference ID 6298779.A live webcast of the call, along with supporting slides, will be available on the investors secti
- Cerevel Therapeutics Announces Positive Topline Results for Darigabat in Phase 1 Clinical Trial in Acute AnxietyIn healthy volunteers, both the 7.5 mg and 25 mg twice-daily doses of darigabat demonstrated a clinically meaningful and statistically significant improvement in the Panic Symptoms List score after eight days of dosing compared with placebo Darigabat was generally well-tolerated; resulted in no serious adverse events and no treatment-related discontinuations in the trialCerevel intends to advance development of darigabat in anxiety-related disordersConference call and webcast scheduled for today at 8:00 a.m. EST CAMBRIDGE, Mass., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience disease
- Cerevel Therapeutics Reports Third Quarter 2021 Financial Results and Pipeline UpdatesPhase 1 data for darigabat in acute anxiety now expected by the end of Q1 2022 Submissions of additional PK/PD data for CVL-231 in schizophrenia accepted for presentation at the Annual Meeting of the American College of Neuropsychopharmacology Conference call and webcast scheduled today at 8:00 a.m. ET CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today reported financial results for the quarter ended September 30, 2021 and provided key pipeline and business updates. "We continue to execute on our vision of becoming the premier neuroscience company as w
- Cerevel Therapeutics to Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021CAMBRIDGE, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report third quarter 2021 financial results and pipeline updates on Wednesday, November 10, 2021, before the U.S. financial markets open. Management will host a conference call to discuss third quarter 2021 financial results and recent pipeline updates on Wednesday, November 10, 2021 at 8:00 a.m. ET. To access the call, please dial 833-665-0655 (domestic) or 702-495-1044 (international) and refer to conference ID 9784674.A live webcast of the call, along with supporting slides, will be a
- Cerevel Therapeutics Reports Second Quarter 2021 Financial Results and Business UpdatesAnnounced positive topline results for CVL-231 in Phase 1b trial in schizophrenia Raised $328 million in net proceeds from follow-on offering of common stock and announced redemption of outstanding public warrants Received Fast Track designation and initiated screening in Phase 2a trial of CVL-871 in dementia-related apathy Virtual R&D Update Event scheduled for October 7, 2021 Conference call and webcast scheduled today at 8:00 a.m. ET CAMBRIDGE, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today reported financial results for the quarter ended June 30, 2021
- Cerevel Therapeutics to Report Second Quarter 2021 Financial Results on Wednesday, August 11, 2021CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report second quarter 2021 financial results and provide a pipeline update on Wednesday, August 11, 2021, before the U.S. financial markets open. Management will host a conference call to discuss second quarter 2021 financial results and recent business and pipeline updates on Wednesday, August 11, 2021 at 8:00 a.m. EDT. To access the call, please dial 833-665-0655 (domestic) or 702-495-1044 (international) and refer to conference ID 8947263. A live webcast of the call, along with suppo